Riik: Kanada
keel: inglise
Allikas: Health Canada
CANDESARTAN CILEXETIL
DOMINION PHARMACAL
C09CA06
CANDESARTAN
8MG
TABLET
CANDESARTAN CILEXETIL 8MG
ORAL
30
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0135220002; AHFS:
CANCELLED POST MARKET
2019-02-07
_Dom-CANDESARTAN Product Monograph_ _Page 1 of 38_ PRODUCT MONOGRAPH PR DOM-CANDESARTAN Candesartan cilexetil tablets 4 mg, 8 mg, 16 mg and 32 mg ANGIOTENSIN II AT 1 RECEPTOR BLOCKER DOMINION PHARMACAL 6111 Av. Royalmount, Suite 100 Montréal, Québec H4P 2T4 DATE OF REVISION : October 19, 2016 Submission Control No: 198053 _Dom-CANDESARTAN Product Monograph_ _Page 2 of 38_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE .............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 8 DRUG INTERACTIONS .................................................................................................. 14 DOSAGE AND ADMINISTRATION ............................................................................. 16 OVERDOSAGE ................................................................................................................ 19 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 19 STORAGE AND STABILITY ......................................................................................... 22 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................. 22 PART II: SCIENTIFIC INFORMATION ............................................................................. 23 PHARMACEUTICAL INFORMATION ......................................................................... 23 CLINICAL TRIALS ......................................................................................................... Lugege kogu dokumenti